The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Larger Will The Trigeminal Neuralgia Treatment Market Become By 2030 Compared To 2026?
The trigeminal neuralgia treatment market size has experienced significant expansion in recent years. It is anticipated to increase from $0.73 billion in 2025 to $0.78 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.7%. The growth witnessed over the historic period can be attributed to factors such as rising diagnosis rates for trigeminal neuralgia, the continued reliance on pharmacological methods for pain management, the expansion of specialized neurology services, enhancements in imaging for nerve disorders, and the increasing availability of surgical treatment alternatives.
The trigeminal neuralgia treatment market is anticipated to undergo significant expansion over the next few years. It is projected to reach $1 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.4%. This growth during the forecast period is attributable to the increasing demand for enduring pain relief solutions, the rising adoption of gamma knife radiosurgery, the expansion of outpatient surgical centers, a growing emphasis on patient quality-of-life outcomes, and advancements in neurosurgical techniques. Key trends expected in the forecast period include a greater use of advanced anticonvulsant medications, an increase in minimally invasive surgical procedures, a growing preference for stereotactic radiosurgery, the broadening of multidisciplinary pain management approaches, and an enhanced focus on long-term symptom control.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21307&type=smp
What Primary Factors Are Fueling The Expansion Of The Trigeminal Neuralgia Treatment Market?
The increasing incidence of neurological conditions is anticipated to drive the expansion of the trigeminal neuralgia treatment market in the future. These disorders encompass various ailments that impact the brain, spinal cord, and nervous system. The growing occurrence of neurological disorders is mainly attributed to the aging demographic, given that advanced age heightens the likelihood of conditions such as Alzheimer’s, Parkinson’s, and stroke. Trigeminal neuralgia treatments assist individuals by alleviating severe facial discomfort, diminishing nerve inflammation, improving their overall quality of life, and averting additional neurological harm. As an illustration, information from the Alzheimer’s Association, a US-based nonprofit voluntary health organization, indicated that in March 2023, roughly 6.7 million Americans aged 65 and above were afflicted with Alzheimer’s dementia in 2023, a figure expected to climb to 13.8 million by 2060. Consequently, the increasing prevalence of neurological disorders is fueling the expansion of the trigeminal neuralgia treatment market. The increasing number of elderly individuals is anticipated to boost the expansion of the trigeminal neuralgia treatment market in the coming years. The term geriatric population denotes people generally 65 years and older, frequently linked with greater healthcare demands stemming from age-related bodily alterations, chronic ailments, and limitations in function. This rise in the older demographic can be attributed to longer life expectancies, progress in medical care, decreased birth rates, higher living standards, more effective disease control, lower infant mortality, better nourishment, and availability of new medical technologies. Treatment for trigeminal neuralgia aids the elderly by mitigating intense facial discomfort, improving their day-to-day capabilities, and elevating the overall quality of life for older individuals. For example, the World Health Organization, a Switzerland-based intergovernmental organization, reported in October 2024 that the worldwide count of people aged 60 and over is estimated to reach 1.4 billion by 2030, representing one in six global inhabitants. This total is forecast to double to 2.1 billion by 2050, while those aged 80 and older are predicted to triple to 426 million. Hence, the aging population is fueling the expansion of the trigeminal neuralgia treatment market.
How Is The Trigeminal Neuralgia Treatment Market Structured Across Different Market Segments?
The trigeminal neuralgia treatment market covered in this report is segmented –
1) By Treatment Type: Medications, Surgery, Other Treatment Types
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Medications: Anticonvulsants, Muscle Relaxants, Antidepressants
2) By Surgery: Microvascular Decompression Surgery, Gamma Knife Radiosurgery, Rhizotomy
3) By Other Treatment Types: Nerve Blocks, Stereotactic Radiosurgery, Physical Therapy
What Trends Are Affecting The Trigeminal Neuralgia Treatment Market Dynamics?
Leading companies in the treatment-resistant depression market are concentrating on creating novel therapies, including monotherapy, to meet unfulfilled patient requirements, enhance effectiveness, and minimize adverse effects. Monotherapy involves employing a solitary treatment or drug to manage a condition, instead of combining it with other interventions. This approach aids in addressing treatment-resistant depression by providing a singular, targeted therapy that could prove more potent for individuals who have not seen improvement with various medications. For example, in January 2025, Johnson & Johnson Services Inc., a pharmaceutical, biotechnology, and medical technology firm based in the US, declared that the U.S. Food and Drug Administration (FDA), a US-based governmental regulatory organization, had approved SPRAVATO (esketamine) nasal spray, a rapid-acting therapy for adults suffering from treatment-resistant depression (TRD). SPRAVATO is administered concurrently with an oral antidepressant when patients have shown insufficient response to a minimum of two prior antidepressant treatments. The swift impact of this medication overcomes the shortcomings of conventional antidepressants, which frequently require several weeks to manifest benefits. As a derivative of ketamine, esketamine functions by targeting the NMDA receptors in the brain, potentially enhancing mood within a few hours. This approval represented a considerable leap forward in the domain of mental health care.
Who Are The Leading Firms Participating In The Trigeminal Neuralgia Treatment Market?
Major companies operating in the trigeminal neuralgia treatment market are Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Pfizer Inc., GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Medtronic plc, Boston Scientific Corporation, Abbott Laboratories, Elekta, Accuray Inc., UCB S.A., Eli Lilly and Company
Access The Complete Trigeminal Neuralgia Treatment Market Report:
Which Region Contributes The Most To The Trigeminal Neuralgia Treatment Market?
North America was the largest region in the trigeminal neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trigeminal neuralgia treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Trigeminal Neuralgia Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=21307&type=smp
Browse Through More Reports Similar to the Global Trigeminal Neuralgia Treatment Market 2026, By The Business Research Company
Fibromyalgia Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/fibromyalgia-treatment-global-market-report
Muscle Pain Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/muscle-pain-treatment-global-market-report
Migraine Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/migraine-treatment-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model